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Daniel H. WisemanRelapse of acute leukemia following hematopoietic stem cell transplantation (HSCT) usually represents re-
turn of an original disease clone, having evaded eradication by pretransplant chemo-/radiotherapy, condition-
ing, or posttransplant graft-versus-leukemia (GVL) effect. Rarely, acute leukemia can develop de novo in
engrafted cells of donor origin. Donor cell leukemia (DCL) was first recognized in 1971, but for many years,
the paucity of reported cases suggested it to be a rare phenomenon. However, in recent years, an upsurge in
reported cases (in parallel with advances in molecular chimerism monitoring) suggest that it may be signifi-
cantly more common than previously appreciated; emerging evidence suggests that DCL might represent
up to 5% of all posttransplant leukemia ‘‘relapses.’’ Recognition of DCL is important for several reasons.
Donor-derivation of the leukemic clone has implications when selecting appropriate therapy, because seeking
to enhance an allogeneic GVL effect would intuitively not have the same role as in standard recipient-derived
relapses. There are also broader implications for donor selection and workup, particularly given the growing
popularity of nonmyeloblative HSCTand corresponding rising age of the potential donor pool. Identification
of DCL raises potential concerns over future health of the donor, posing ethical dilemmas regarding respon-
sibilities toward donor notification (particularly in the context of cord blood transplantation). The entity of
DCL is also of research interest, because it might provide a unique humanmodel for studying themechanisms
of leukemogenesis in vivo. This review presents and collates all reported cases of DCL, and discusses the
various strategies, controversies, and pitfalls when investigating origin of posttransplant relapse. Putative eti-
ologic factors and mechanisms are proposed, and attempts made to address the difficult ethical questions
posed by discovery of donor-derived malignancy within a HSCT recipient.
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Secondary malignancy is an important cause of
morbidity in transplantation practice, but its occur-
rence in tissues of donor origin is rare. One study of
108,062 solid-organ transplants detected 21 examples,
for a reported incidence of 0.017% [1]. Allogeneic hem-
atopoeitic stem cell transplantation (HSCT) is an effec-
tive treatment for many hematologic malignancies, but
disease relapse remains a major cause of posttransplant
mortality [2]. Most cases represent recurrence of origi-
nal disease through outgrowth of residual cells having
evaded eradication by conditioning or graft-versus-
disease effect. Occasionally, relapsed disease mayHaematology Department, Manchester Royal Infirmary,
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from the original disease. This may be because of a lin-
eage switch (eg,myeloid to lymphoid blast crisis), clonal
evolution, or emergence of latent surviving subclones
[3], but usually the relapse clone is host derived. Rarely,
acute leukemia can develop de novo in donor-derived
cells. Reporting of so-called ‘‘donor cell leukemia’’
(DCL) has accelerated in recent years, and this in-
triguing entity is the subject of considerable interest
for the unique insights into the mechanisms of leuke-
mogenesis it might provide.
Incidence of DCL
DCLwas first described by Fialkow and colleagues
in 1971 [4]. A 16-year-old female patient with acute
lymphoblastic leukemia (ALL) relapsed 62 days after
bone marrow transplant (BMT) from an HLA-
identical brother. Cytogenetics at relapse revealed
only male (XY) metaphases, leading the authors to
conclude that leukemic transformation had occurred
in progeny of engrafted donor bone marrow (BM)
cells. They implicated activation of a leukemogenic
agent in susceptible donor cells in this process. Further
cases have been reported sporadically since, mostly as
isolated reports and small series. Efforts to estimate771
Figure 1. Number of reported cases of donor cell leukemia (DCL) by year of publication (1971-2010).
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nature of reports and habitual difficulties in confirm-
ing the diagnosis. In 1982, Boyd et al. [5] suggested
that DCL might account for $5% of posttransplant
leukemia relapses, although for many years, the pau-
city of reports suggested this to be a gross overesti-
mate. Recently, however, frequency of reporting has
accelerated with more cases reported since 2004 than
during the previous 34 years (Figure 1). In 2005, a ret-
rospective survey by the European Group for Blood
and Marrow Transplantation (EBMT) asked all regis-
tered centers to report any cases of suspected or proven
DCL encountered at their institutions, identifying 14
cases [6]. Because the 91 responding centers had per-
formed a total 10,489 procedures, DCL incidence
was estimated at 124 per 100,000 transplants. Most oc-
curred within 4 years of HSCT, suggesting an annual
incidence greatly exceeding the background incidence
of acute leukemia. In 2006, Salla-Torra et al. [7] re-
ported 6 cases identified at their institutions since
1974, and Ruiz-Arg€uelles et al. [8] prospectively dem-
onstrated donor origin in 2 of 40 consecutive relapses
for a putative incidence of 5%: a figure intriguingly
similar to that proposed by Boyd 24 years earlier.
Using various PubMed searches, we have identified
51 cases of suspected or proven DCL in the English
literature, along with 13 cases of donor cell–derived
myelodysplastic syndrome (DCM) lacking evidence of
transformation to frank leukemia at time of publication
[4,6-57] (Table S1). DCM cases with evidence of clon-
ality, high-risk features, or progression toward acute
myelogenous leukemia (AML) were included in the co-
hort; these probably share comparable epidemiologic
and biological features with other DCLs and represent
the same phenomenon detected at an earlier stage,
supported by the observation that at least 11 cases of
frank DCL apparently displayed an antecedent myelo-
dysplastic phase.
DCL Cohort Characteristics
Patients reported to have developed DCL appear
to be a heterogeneous cohort, with characteristicsand transplant details broadly reflecting those for the
general HSCT population. Summary characteristics
are presented in Table 1. Median age at transplanta-
tion of patients developingDCLwas 31.0 years (range:
1–61), with 18 (29%) aged #16 years and no discern-
able sex preponderance (32 male/32 female). Patients
who received myeloablative (MA) conditioning were
younger than those receiving nonmyeloablative
(NMA) conditioning (29.5 versus 40 years). Intuitively,
donor age might influence the risk of leukemia devel-
oping in their donated HSCs. Median donor age
(in non-cord blood transplants) was 22.0 years, but
this information was only provided in 17 of the 60 re-
ports. Where both ages were provided, donors were
older than recipients in 9 (of 16) cases, by an average
of 3.6 years. Donors were female in 34 (53%) and
male in 30 (47%), with recipient/donor sex mismatch
present in 40 (63%) cases (including 17 of the 20 ear-
liest reports).
Primary diagnosis was chronic myeloid leukemia
(CML) in 17 (26%) cases, including 2 in lymphoid
blast crisis; AML in 10 (16%); ALL in 17 (26%); and
myelodysplastic syndrome (MDS) in 3 (5%), including
a therapy-related MDS after treatment for chronic
lymphocytic leukemia (CLL). Seven patients (11%)
were transplanted for aplastic anemia (AA). Single re-
ports describe DCL after juvenile myelomonocytic
leukemia, myeloid/natural killer cell precursor acute
leukemia, multiple myeloma, follicular lymphoma,
Hodgkin lymphoma, adult T cell lymphoma/leukemia
(ATL), beta-thalassemia, Langerhan’s cell histiocyto-
sis, and renal cell carcinoma. We recently observed
a case of DCL following HSCT for primary (aleuke-
mic) granulocytic sarcoma. DCL type was AML in
34 (53%) cases and ALL in 16 (25%). Another was de-
scribed as CML in lymphoid blast crisis. DCL differed
from original disease in 46 (72%) cases, with demon-
strable phenotypic, cytogenetic, or subclassification
differences present in many others. In addition to 13
DCM cases, an antecedent MDS phase was diagnosed
in at least 11 of the 34 donor-derived AML cases
(32%). Others might have also followed an MDS
Table 1. Patient, Donor, and Transplant Characteristics for
the 64 Reported Cases of Donor Cell Leukemia
Patient Characteristics
Sex Data Missing
Male 32 (50%) 0
Female 32 (50%)
Age at transplant (median 31.0 years)
<10 10 (16%) 1
10-19 10 (16%)
20-29 9 (14%)
30-39 16 (25%)
40-49 13 (21%)
$50 5 (8%)
Primary diagnosis
AML 10 (16%) 0
ALL 17 (26%)
CML 17 (26%)
MDS 3 (5%)
AA 7 (11%)
Other (single cases) 10 (16%)
DCL type
AML 34 (53%) 0
ALL 16 (25%)
MDS 13 (20%)
Other 1 (2%)
Donor characteristics
Donor
Sibling 47 (74%) 0
Other relative 4 (6%)
VUD 9 (14%)
Cord 4 (6%)
Sex
Male 30 (47%) 0
Female 34 (53%)
Age at donation (median 22.0
years)
<10 4 (23%) 43
10-19 4 (23%)
20-29 2 (12%)
30-39 3 (18%)
40-49 4 (24%)
$50 0
Transplant details
HSC source
BM 45 (70%) 0
PB 15 (24%)
CB 4 (6%)
Conditioning
Myeloablative 57 (89%) 0
Nonmyeloablative 7 (11%)
TBI with CP (±other drugs) 26 (44%) 3
TBI without CP (±others) 7 (11%)
TLI/TAI with CP (±others) 2 (3%)
CP + BU (±other drugs) 16 (26%)
CP (±other drugs) 8 (13%)
Other 2 (3%)
Alkylating agent 55 (90%)
Topoisomerase II inhibitor 20 (33%)
Irradiation (TBI/TLI/TAI} 35 (57%)
T-depletion of graft
Ex vivo 4 (*) *
In vivo (ATG/alemtuzumab) 10 (*)
GVHD prophylaxis
CSA with MTX (±others) 31 (57%) 10
CSA without MTX (±others) 13 (24%)
MTX without CSA (±others) 9 (17%)
Other 1 (2%)
CMV reactivation 8 (*) *
Chronic GVHD 23 (*) *
Extensive 7 (*)
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic
leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syn-
drome; AA, aplastic anemia; VUD, volunteer unrelated donor; HSC,
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from the published report. Patients displaying an
MDS phase were significantly older (median 36 versus
27 years), perhaps suggesting that DCL might repre-
sent a convergent endpoint of distinct mechanisms of
leukemogenesis. Forty-six percent of cases document-
ing donorMDS had transformed to frank AML at time
of publication, but this apparently high transformation
rate might simply reflect a higher sensitivity of detect-
ing antecedant MDS, given the intensive monitoring
afforded to patients after HSCT.
The donor was related to the recipient in 80% of
cases (47 siblings; 1 HLA-identical mother; 3 other hap-
loidentical relatives). Only 9 (14%) involved a volunteer
unrelated donor (VUD).HSCsourcewasBMin45 cases
(70%), peripheral blood (PB) in 15 (24%), and cord
blood (CB) in 4 (6%). Conditioning was MA in 57
(89%) and NMA in 7 cases (11%). Details of condition-
ing regimens were provided for 61 cases, in which 28 dif-
ferent combinations were used. Total-body irradiation
(TBI) was used in 33 (54%) cases, with 2 others employ-
ing total lymphoid and thoracoabdominal irradiation.
Overall, cyclophosphamide was used in 52 cases (85%):
alongside TBI in 26 (44%) and busulfan in 16 (26%)
cases.The 7NMA transplants employed 6 different con-
ditioning regimens. Overall, 90% received alkylating
agents, although to infer this as an independent risk
factor for DCL would be tautologous given the near-
ubiquitous usage of alkylators in conditioning regimens.
The heterogeneous nature of the few reported cases pre-
cludes identification of independent risk factors, with no
significant trends in T cell depletion, engraftment kinet-
ics, graft-versus-host disease (GVHD), cytomegalovirus
(CMV) reactivation, or other viral complications emerg-
ing from the information available.
Standard leukemia relapse post-HSCT is consid-
ered a relatively early event. In a series of 6,691 pa-
tients disease free at 2 years, only 4.5% ultimately
died of relapsed disease [58], whereas another revealed
no relapses after 3 years [59]. In contrast, DCL appears
to be a relatively later complication, with median
time-to-DCL of 31 months (range: 2-312 months).
(Where an antecedent MDS phase was diagnosed be-
fore evolution to frank leukemia, first diagnosis of
MDS was considered as time of malignant transforma-
tion.) Time-to-DCL was significantly longer in those
cases involving antecedentMDS, with or without overt
transformation (median 43.5 versus 18.0 months; P 5
.014), again supporting the notion of distinct disease
processes.hematopoietic stem cell; BM, bone marrow; PB, peripheral blood; CB,
cord blood; TBI, total-body irradiation; CP, cyclophosphamide; TLI, total
lymphoid irradiation; TAI, thoracoabdominal irradiation; BU, busulfan;
ATG, antithymocyte globulin; GVHD, graft-versus-host disease; CSA,
cyclosporine; MTX, methotrexate; CMV, cytomegalovirus.
*Details rarely/inconsistently provided in published reports.
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Diagnosis of DCL depends on accurate and un-
equivocal demonstration of donor derivation of the
leukemic clone. Until recent years this was difficult
and hampered by many pitfalls. Several strategies
have been employed, sharing the fundamental goal of
identifying differences in genetic material between do-
nor and recipient amenable to reliable investigation in
the relapse clone. In practice, most approaches provide
only indirect evidence of donor derivation through
demonstration of complete donor chimerism (ie, lack
of residual host hematopoiesis).Conventional cytogenetics and fluorescent in situ
hybridization (FISH)
Suspicion of donor origin in most early cases de-
rived solely from the unexpected presence (or absence)
of the Y chromosome in relapse BM specimens, in the
context of sex-mismatched HSCT. Conventional
banding techniques, developed in the 1960s, permitted
differential staining of chromosomes cultured in meta-
phase and their identification based on distinctive
banding patterns. Fialkow and coworkers’ original
DCL report concluded donor origin on the observa-
tion of Y chromosomes in all of 58 marrowmetaphases
on G-banding cytogenetics in a female transplant re-
cipient [4]. The logical assumption was that leukemic
transformation had occurred in engrafted donor cells,
although the otherwise normal karyotype and lack of
cell sorting precluded unequivocal confirmation that
the visualized karyotype belonged to the leukemic
clone. Nevertheless, at relapse, lymphoblasts repre-
sented 80% of total nucleated BM cells, so the finding
of 46,XY in all metaphases inspected was considered
sufficiently conclusive. Until the 1990s, demonstration
of sex mismatch in this manner remained the mainstay
of DCL diagnosis, occasionally supported by fluores-
cent Y body detection in interphase cells (a technique
exploiting the bright staining of Y chromosome long
arms with certain dyes).
However, conventional cytogenetics relies on cap-
turing cells in metaphase and consequently requires ac-
tive, spontaneous cell division. It is well recognized that
leukemic cells can display lower proliferative rates than
healthy cells (with clinical disease resulting from their
gradual accumulation over time) [60]. Thus, a slowly
dividing residual host leukemia could be outpaced by
normal donor cells in culture and remain undetected,
even when blasts vastly outnumber normal donor cells
in BM. Certain methods used to prepare and capture
metaphases can even suppress and select against leuke-
mic cells in culture [61]. In contrast to healthy cells,
leukemic metaphases are often of poor quality, because
of inherent genomic instability and prior exposure to
damaging chemo-/radiotherapy. Several early DCL
reports noted a significant proportion of damaged,uninterpreble mitoses at relapse (eg, 30% in case #3
[10]); potentially, these could have harbored an
aberrant residual host leukemic clone. In case #1,
whereas uncultured BM yielded only healthy looking
46,XY (donor) metaphases, most phytohemagglutin-
stimulated cells demonstrated severe radiation damage
with extensive chromosome fragmentation; only 4 were
suitable for analysis, all of which displayed XX (host)
karyotype and so conceivably might have represented
the leukemic clone [4].
The introduction of FISH provided an additional
tool for investigating origin of leukemic relapse, with
the notable advantage of assessing cells in interphase,
independent of mitotic rates. Despite yielding limited
karyotypic information, FISH permits rapid enumera-
tion of preselected chromosomes and DNA sequences
to aid characterization of relapse clones and investigate
donor-recipient chimerism. The ability of FISH to
screen large numbers of cells (often$500) with fluoro-
phores for sex chromosomes permits reliable detection
of residual recipient hematopoiesis with sensitivity
\1% [62]. The absence of mixed chimerism by
FISH provided corroboratory evidence of DCL in at
least 18 of the 28 cases of sex-mismatched DCL, after
Mouratidou et al. first employed this approach in 1993
[24]. In some cases, FISH directly correlated the pres-
ence of new leukemia-defining autosomal abnormali-
ties alongside donor-type sex chromosomes within
the same cell (eg, Y and –7 in case #64), whereas in
case #17, Lowsky et al. used FISH to localize –7 and
XX (donor-karyotype) to myeloblasts morphologically
[26]. Others inferred DCL from absence of minimal
residual disease by FISH analysis in cases with a previ-
ously known cytogenetic marker.
However, any approach based on assessing chime-
rism by sex chromosomes remains applicable in only
50% of transplant pairs, and will retain other limita-
tions. Genomic instability and clonal evolution of
leukemic cells frequently introduce new chromosomal
abnormalities, and the propensity of blasts to lose or
gain sex chromosomes is well recognized [63]. Y loss
(–Y) is particularly common, observed in 3.4% to
6.3% of male leukemia patients [64,65] and even in
healthy males with ageing [66]. Any altered X/Y-
ploidy could potentially mislead toward erroneous sus-
picion of DCL. Anastasi et al. reported an ALL relapse
in a male patient transplanted from his sister, involving
98% BM infiltration with normal female karyotype in
40 metaphases. However, the original disease clone
had displayed complex karyotype, including gain of
2X chromosomes (XXXY). FISH of 1000 interphase
nuclei revealed trisomy X (1X) in 83%, Y in 85%,
and 117 (also present in the original clone) in 75%,
confirming host origin of the disease clone [67].
Similarly, Perla et al. [68] disproved suspected DCL
in a female CML patient displaying 46,XY karyotype
at relapse, because FISH showed 2 times hybridization
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of the original disease a more likely diagnosis) [68].
Although in these examples FISH correctly refuted
DCL, this might not always have been the case. In
DCL case #4, 42 of 64 relapse metaphases in a female
recipient displayed 45,X0,t(8;21), with the absence of
Y by FISH apparently confirming DCL [11]. How-
ever, the same picture could have resulted from relapse
of the original disease with clonal evolution of new
abnormalities: –Y/t(8;21); indeed, an earlier chloroma
relapse had contained recipient-type XY cells only.
Molecular DNA markers
Some early DCL reports noted autosomal
‘‘markers’’ displaying a different staining intensity
between donor and recipient on metaphase spreads.
These were presumed to represent distinctive genetic
polymorphisms capable of distinguishing their origin
irrespective of sex. In case #3, the relapse 45,X0 karyo-
type left the donor (female) or host (male) derivation
uncertain, but quinacrine staining revealed bright cen-
tromere fluorescence on chromosome 3 in donor fi-
broblasts that was lacking from pretransplant host
BM cells [10]. A similar bright satellite on chromo-
some 21 in case #5 permitted diagnosis of DCL with-
out sex mismatch for the first time [12]. Although the
putative markers were not further characterized, these
heralded future strategies of distinguishing donor
from host based on idiosyncratic sex-independent
genetic polymorphisms.
Subsequently, a variety of neutral DNA sequences
(lacking known transcription function) were found to
display considerable polymorphism within the popula-
tion. Stably inherited as codominant Mendelian traits
and propagated to all cells, these constituted a reliable
set of markers for identifying cells originating from
a particular individual and proved ideal targets for chi-
merismmonitoring. Any transplant recipient may have
up to 4 different alleles of a particular marker, depend-
ing on degree of zygosity, allele sharing, and chime-
rism between donor and recipient. Any informative
donor allele (ie, absent in the recipient) can act as a use-
ful marker to identify presence of donor-type hemato-
poiesis within the recipient. Restriction fragment
length polymorphisms (RFLP) arise from variations
in the length of DNA fragments generated after diges-
tion by restriction endonucleases at specific cleavage
sites. Variation results either from mutations altering
integrity of enzyme recognition sites or from addition
of neutral DNA between them (which can vary widely
in size between individuals) [69]. The RFLP locus
D14S1, identified in 1980 and localized to a highly
polymorphic immunoglobulin heavy chain (IgH) re-
gion on chromosome 14, enabled Witherspoon et al.
(case #8) to diagnose DCL following sex-matched
HSCT [16]. Hybridization of DNA from recipient fi-
broblasts with a plasmid probe homologous to D14S1yielded bands of 19 and 16 kb, compared with bands of
16 and 12 kb in both relapse BM and donor mononu-
clear cells, thereby distinguishing the genotypes and
confirming donor origin that would have remained un-
suspected by standard methods. Feig et al. (#11) [20]
and Orciuolo et al. (#32) [41] employed similar tech-
niques; conversely, RFLP enabledMinden et al. to dis-
prove suspected donor origin of AML in amale patient
following BMT from his brother [70].
Some RFLPs were found to arise from polymor-
phic variations in number of tandemly repeated
sequences of ‘‘junk’’ DNA in the nonencoding regions
of genes. This heralded identification of variable
number of tandem repeats (VNTRs), sequences 7-100
nucleotides in length generally concentrated at telo-
meres, and short tandem repeats (STRs): shorter (2-6
nucleotides), more numerous and widely dispersed
throughout the genome. Both provide markers dis-
playing high degrees of polymorphism, amenable to
amplification by polymerase chain reaction (PCR)
and capable of detecting persistence of a minor
recipient-derived clone to high sensitivity [71]. STR-
based techniques have largely superceded VNTRs
owing to availability of commercial multiplex kits,
ease of automation, and the high degree of STR poly-
morphism [72]. Tandem repeats were first applied to
DCL in 1991 (case #12), in which PCR of 7 informa-
tive microsatellite sequences confirmed full donor
chimerism in a male patient diagnosed with AML 9
months after sex-mismatched BMT—supporting the
observation of 46,XX,t(9;11) in 20/20 metaphases.
The stated sensitivity of the test (‘‘0.01%’’) effectively
excluded the possibility of a recipient clone of suffi-
cient size to explain the observed 90% BM infiltration
by AML [21].
Since 1993, at least 39 (of 51) DCL diagnoses
relied predominantly on 100% donor chimerism by
VNTR or STR PCR. However, these approaches
too carry limitations. Although applicable equally to
sex-matched and -mismatched transplants, at any lo-
cus, 25% of sibling pairs will have inherited identical
alleles and thus lack an informative marker. Moreover,
in practice, coamplification of alleles generally limits
the detection sensitivity of current VNTR/STR PCR
techniques to 1% of the minor component (ie, 1
recipient cell in100). With substantial allele size dif-
ference, preferential amplification of smaller alleles
may cause allelic dropout and further reduce detection
sensitivity of the larger allele. PCR-based assays are
prone to contamination, with proportionally greater
impact at higher levels of sensitivity. Theoretically,
these permit low-level residual recipient hematopoie-
sis to persist undetected, although by definition,
DCL must involve a proportion of leukemic blasts
well in excess of the detection limits of the test.
Importantly, total/partial chromosomal deletions
in the inherently unstable disease clone will remove
776 Biol Blood Marrow Transplant 17:771-789, 2011D. H. Wisemanany marker/s located on the corresponding segment,
with loss of heterozygosity and potentially misleading
results even for a theoretically informative marker.
For example, where a single allele is shared by both
parties, loss of the unique informative donor allele
from the disease clone would convert the apparent ge-
notype to that of the recipient. Stein et al. highlighted
this potential source of error in amale patient following
BMT from his sister [73]. Cytogenetics initially sug-
gested DCL, with 46,XX karyotype, negative Y-body
fluorescence, donor-type banding heteromorphism
on chromosome 9qh, and absence of the original
t(18;21) from all visualized metaphases. Two RFLP
probes (pDP105, pDP132) initially corroborated suspi-
cion of DCL. However, these loci are situated on the Y
chromosome, and RFLPs from chromosomes X (St14-
1/S-232), 5p (L4-123), and 21q (L4-427) revealed
.90% recipient chimerism, confirming hematopoiesis
to be dominated by recipient-derived lymphoblasts.
Schichman et al. described 2 instances of informative
STR allele loss because of hypoploidy in 140 HSCT
recipients [74]. One involved a female CML patient
relapsed in blast crisis after sex-mismatched BMT,
with 46,XX,t(9;22) and partial deletion of chromosome
3, consistent with evolution of the original clone. Both
donor and recipient were heterozygous for the
D3S1358 STR (on chromosome 3p) with no shared al-
leles. Although host derivation of relapse was con-
firmed by presence of the recipient-type 18kb peak,
the authors noted absence of the other recipient allele
(16kb), consistent with the single chromosome 3p dele-
tion. Had the deleted 16kb peak been the only informa-
tive allele (ie, donor homozygous for the 18kbmarker),
DCL might have been erroneously suspected. Simi-
larly, Zhou et al. [75] reported an initially aberrant re-
sult mimicking 100% donor engraftment from VNTR
PCR of the apoB locus in a patient with near-haploid
karyotype at CML relapse.
Therefore, several markers across different chro-
mosomal loci should always be sought and correlated
with evaluation of the relapse karyotype. However,
without an unequivocal marker of clonality the appar-
ent absence of recipient hematopoiesis remains only
an indirect indicator of DCL. Spinelli et al. [76] re-
ported presumed DCL in a male patient transplanted
from his sister for Philadelphia-positive ALL, in which
DCL was suggested by 46,XX karyotype, absence
of the Y-specific DYS14 VNTR and 100% donor-
type YNZ-22 VNTR (chromosome 17) by PCR.
Nevertheless, the authors considered the possibility
of comigration of 2 alleles, and sequencing of the
CDRIII region of the IgH gene revealed a unique
DNA rearrangement identical to that in the original
disease clone, proving relapse to be recipient derived.
The authors advocated need for ‘‘accurate and exten-
sive molecular characterization to prove donor
origin of a leukemia relapse’’ with identification ofleukemia-specific sequences perhaps the only defini-
tive tool for this purpose.
Nevertheless, provided a sufficient number of infor-
mative alleles are examined, STR chimerism analysis
should reliably confirm DCL in most cases, and repre-
sents a major advance on earlier methods reliant solely
on sex mismatch by conventional cytogenetics. Conse-
quently, the validity of some early DCL diagnoses have
beenquestioned, and it is noteworthy that in 8 of the first
10 reports,DCL typewas identical to that of the original
disease (true only in 10 of the subsequent 54 cases, most
of which employed molecular techniques). Newer dia-
llelic polymorphic markers including single nucleotide
polymorphisms and short inversion/deletion polymor-
phisms have the additional advantage of permitting am-
plification of each allele separately, negating the effects
of competitive amplification and permitting more sensi-
tive detection of mixed chimerism [77,78]. Investigating
origin of relapses in future should be enhanced by their
potential for superior sensitivity (approaching 1024 to
1026 of the minority cell population [79]).Etiology of DCL
The leukemic transformation of previously healthy
donor HSCs provides a useful in vivo model for inves-
tigating the mechanisms involved in leukemogenesis.
It presents a unique opportunity to prospectively study
the events experienced byHSCs leading to theirmalig-
nant transformation, because leukemia in the general
population is usually sporadic and unpredictable,
whereas HSCT patients are routinely subjected to rel-
evant and repeated investigations; these are informa-
tive prospectively but also provide useful samples for
retrospective analysis. From the limited data available,
any discussion of the mechanisms driving donor cell
transformation is highly speculative, and the heteroge-
neity of documented cases precludes identification of
a single mechanism or unifying hypothesis. Neverthe-
less, some published cases provide intriguing clues,
and several putative theories have been proposed
(Figure 2). DCL oncogenesis is probably a multifacto-
rial process involving the convergent interplay of
different influences. A multiple ‘‘hit’’ hypothesis ap-
pears plausible, by which HSCs primed within the
donor (eg, an inherited primary caretaker gene defect)
experience second/subsequent critical ‘‘hits’’ after
transplantation into an aberrant donor environment,
unusually supportive for realization of this malignant
potential. A high frequency of antecedent MDS and
complex karyotypes perhaps supports the notion that
multiple genetic events might occur in at least some
DCL cases.
Occult leukemia in the donor
The simplest explanation for apparent DCLwould
be that of an undetected malignant clone present
Figure 2. Proposed mechanisms and other etiologic factors influencing development of donor cell leukemia (DCL). Several putative mechanisms have
been proposed to contribute critical ‘‘hits’’ toward leukemogenesis in cells of donor origin following transplantation into a new host. Genetic factors
might prime stem cells with a preleukemic phenotype within the donor, with a range of recipient- and therapy-specific factors probably interacting
to contribute toward realization of malignant potential following engraftment into the more conducive bone marrow environment of the recipient.
A ‘‘multiple hit’’ hypothesis has been proposed, with DCL probably the convergent endpoint of numerous distinct pathways (which may vary between
individual cases).
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wieser et al. [80] have reported inadvertent transmis-
sion by BMT of occult AML into a CML patient, in
which the donor had been aleukemic at donation but
developed frank AML shortly afterward. Six months
after infusion of the contaminated graft, AML became
clinically evident in the recipient, displaying identical
morphologic, phenotypic, and cytogenetic character-
istics to the donor’s disease [80]. Accidental transplan-
tation of CML [81] and cutaneous T cell lymphoma
[82] have also been reported. Transfer of even a small
minority clone can result in clinical disease. Mielcarek
et al. described long-term engraftment and clonal
dominance of an MDS clone transplanted from an
asymptomatic 50-year-old female into her sister [83].
The donor’s MDS was diagnosed retrospectively,
characterized by del(20q) in 18% BM cells. Cells bear-
ing del(20q) steadily increased in the recipient, from
10% after 5 months to 73% at 7 years. Because T
and B cells were part of the abnormal, clone del(20q)
must have arisen in amultipotent progenitor cell, dem-
onstrating capacity of a low-level donated clone to
ultimately dominate hematopoietic reconstitution.Sala-Torra and coworkers’ [7] series included 6
examples of hematologic malignancy directly trans-
mitted through HSCT (3 CLL; 1 each marginal
zone lymphoma, mantle cell lymphoma, ALL). Dis-
ease clones detected in recipients displayed identical
immunophenotype and/or clonal IgH gene rearrange-
ment to the corresponding donor’s disease. Inadver-
tent transmission of malignant clones might be
surprisingly common, and intuitively might increase
with the rising popularity of NMA HSCT and corre-
sponding increase in age of sibling donors. Nieder-
wieser et al. [84] addressed this in detail and outlined
stringent recommendations for donor workup. Kiss
et al. [85] starkly demonstrated the potential risk, hav-
ing discovered 3 incidental malignancies (myeloma,
CLL, MDS) in potential donors during routine
workup BMs in a single year. However, no donors
were diagnosed with leukemia in the 46 cases of idio-
pathic DCL for which donor follow-up was reported
(median follow-up 48 months). Many had been re-
called for PB/BM screening, and extended literature
search revealed no updated reports of leukemia in
any of the donors in question.
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Alternatively, outwardly healthy donor HSCs
might have been previously endowed with genetic
premalignant potential (either inherited or acquired).
Hereditary predisposition to MDS/AML has been de-
scribed with CEBPA and RUNX1 gene mutations, and
12 pedigrees with familial –7 and MDS/AML have
been identified [86]. A high incidence of MDS/AML
also occurs in several familial cancer predisposition
syndromes, characterized by germline mutations in tu-
mor suppressor/DNA repair genes, genomic instabil-
ity, and accrual of oncogenic mutations. Li Fraumeni
syndrome (associated with p53 defects) carries an
estimated leukemia risk of 10% [87], whereas the
chromosomal breakage disorders Bloom’s syndrome
and Fanconi anemia confer lifetime MDS/AML risk
of 20% to 25% and 35% to 50%, respectively
[88,89]. Even without a defined syndrome, Shpilberg
et al. [90] reported an odds ratio of 3.62 for hemato-
logic malignancy in relatives of 189 affected patients;
most diseases differed from the index case, suggesting
a defect in a pluripotent HSC with additional environ-
mental factors dictating progression to different
lineage-specific malignancies.
In the 80% of DCL cases involving related donors,
any genetic predisposition might have been shared by
both parties, with malignant potential more likely to
be realized in the favorable posttransplant microenvi-
ronment of the recipient. In case #32, both recipient
and donor developed MDS within weeks of each other
18 years after HSCT. STR analysis confirmed donor-
derivation of the recipient’s disease, yet the 2 sisters
had led independent lives, in different areas with unre-
lated lifestyles. The authors concluded the late con-
temporaneous onset of similar disease to suggest
intrinsic damage in the donor HSCs themselves [41].
Interestingly, although the recipient’s disease was
rapidly progressive, the donor displayed only modest
cytopenias and stable blast percentage, suggesting a de-
gree of immunologic control in the immunocompetent
donor. The donor in case #28 developed high-grade
non-Hodgkin lymphoma (NHL) at age 17, 13 years af-
ter donating BM to her brother. Amutation at position
2281 of the BLM gene was later detected in the donor,
consistent with Bloom’s syndrome; the recipient had
died (of DCL) and could not be tested [37]. In case
#25, the donor (a lifelong nonsmoker) developed squa-
mous cell bronchial carcinoma 15 months after donat-
ing BM to his brother, who developedDCL 33months
later. Screening for a p53mutation was negative, but 3
unrelatedmalignancies in 2 siblings strongly suggested
a shared genetic predisposition to malignancy [34].
The donor in case #35 developed breast cancer 10
months after donating [44]. Although familial predis-
postion was not mentioned in other cases, detailed
pedigree analysis was not presented, and it is unlikelythat donors had been routinely screened for such
mutations. Moreover, in Li Fraumeni syndrome,
only 50% to 70% patients have an identifiable p53
mutation, and other syndromes display variable pene-
trance. Apart from the few well-described syndromes,
much about familial predisposition to cancer remains
obscure.
With an unrelated donor, the likelihood of shared
predisposition becomesmuch less plausible, and only 9
cases of DCL have been reported in this setting. Nev-
ertheless, VUDHSCs might still harbor premalignant
potential, due either to coincidental genetic predispo-
sition or environmental exposure to genotoxic stimuli.
The donor in case #17 had previously received the al-
kylating agent dacarbazine for malignant melanoma,
which might have rendered donor HSCs sensitive to
secondary stresses following transplantation; the find-
ing of –7 was consistent with a therapy-related AML.
The donor remained healthy after 9 years [26]. Al-
though no specific donor risk factors were described
in any other cases, relevant background information
(eg, drug/employment history) was rarely presented.
An interesting observation is the frequency with
which latent premalignant clones occur in the normal
population. Bcr-ablmRNAwas found in30% of nor-
mal adults [91] and t(14;18), a recurring abnormality in
follicular lymphoma, was detectable in 24% of healthy
individuals [92]. Latent abnormal clones might be
particularly common in CB donations. Uckun et al.
[93] showed that MLL-AF4 fusion transcripts charac-
teristic of infant ALL were present in 25% of fetal
BM samples. PCR screening of CB samples revealed
a significant frequency of potentially preleukemic
clones (1% TEL-AML1, 0.2% AML-ETO) [94],
but the 100-fold lower incidence of subsequent leu-
kemia indicates a need for additional postnatal events.
Up to 5% of CB samples might harbor potentially pre-
leukemic clones, raising the possibility that DCL
might be disproportionately common after cord blood
transplantation (CBT) [95].
Viral transfection/integration
Thenotion of a leukemogenic virus has always been
attractive, not least for DCL, in which recurrence of
a similar (but distinct) disease develops within an
individual despite eradication of the original culpable
clone. Parallels have been drawn with other neoplasms
of proven viral etiology. The neoplastic lymphoid
proliferation of posttransplant lymphoproliferative
disorder (PTLD) is driven by EBV infection of
B-lymphocytes, which in the context of dysregulated
T cell immunity can facilitate B cell immortalization
and uncontrolled proliferation [96]. Although PTLD
following solid organ transplantation is usually recipi-
ent derived HSCT-associated PTLD is almost always
donor in origin. This holds even when the donor is
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into donor cells occurs after transplantation. However,
PTLD is driven at the level of the mature lymphocyte,
and it is difficult to purport an analogous role for EBV
in transforming the more primitive cells responsible
for DCL. ATL is another aggressive lymphoprolifera-
tive disorder, occurring exclusively in the context of
infection by the retrovirus HTLV-1. Although mecha-
nisms are not fully understood, roles for the HTLV-
1–encoded proteins Tax (which can inactivate p53 and
p16) and HBZ (which supports T cell proliferation)
appear likely. However, only 2% to 6% of HTLV-1
carriers develop ATL (after a latency of 50-60 years
from infection), implicating roles for additional genetic
and epigenetic factors [97]. Examples of donor-derived
ATL following HSCT have been described, with uni-
formly shorter latency than for standard ATL. Tamaki
and Matsuoka reported a recurrence of ATL (in PB) 4
months after HSCT for lymphoma-type ATL. Source
of infecting virus was uncertain, because both recipient
and donor were HTLV-seropositive, but STRs
confirmed 100% donor engraftment [98]. Ljungman
et al. detected HTLV-1 in PB lymphocytes of an
ATL patient following HSCT from an HTLV-
1–seronegative sibling, demonstrating the capacity for
leukemogenic viral material within the host to rapidly
transfect virus-na€ıve donor cells [99]. Although neither
PTLD nor ATL are directly analogous to DCL, the
potential for prior therapy to release a comparable,
hitherto-unidentified oncogenic virus for transfection
into donorHSCshasbeenproposed (although support-
ive evidence is lacking).
Oncogene integration/fusion
Some have taken this idea further and speculated
that other (nonviral) leukemogenic material, most
likely a dominant oncogene, might be released by con-
ditioning from residual leukemia cells and directly
transfect the genome of donor HSCs. Theoretically,
the radiation damage rendered by TBI could release
intact portions ofDNA,whichmight survive in a viable
state to be incorporated into donorHSCs proliferating
nearby. However, even allowing for a degree of clonal
evolution, the ensuing DCL phenotype should closely
resemble that of the original disease; this was only ob-
served in 18 cases (28%). Alternatively, leukemic cells
surviving conditioning might fuse with incoming
donor HSCs, with diploidization yielding cell lines
bearing recipient-derived leukemic factors and donor-
derived chromosomes. The notion of cell fusion as
a mechanism of oncogenesis dates from the 19th cen-
tury when Hansemann proposed malignancy to result
from hybridization between leucocytes and somatic
cells.Whereas somatic cell fusion usually results in ter-
minally differentiated multinuclear cells incapable of
proliferation, malignant cells display high rates of
spontaneous fusogenicity, resulting in proliferatinghybrids characterized by a high degree of aneuploidy
[100]. Mechanisms remain unclear, but certain viruses
can mediate cell fusion via specific proteins [101], and
Duelli et al. [102] showed that an otherwise harmless
virus caused massive chromosomal instability through
fusing cells whose cycles had been disrupted by onco-
genes, with some producing aggressive, aneuploid ep-
ithelial cancers in mice. Whether these have relevance
to DCL is unclear, but the opportunity for such fu-
sions would theoretically exist in the posttransplant
environment, and could conceivably cause residual
host disease clones to masquerade as DCL at relapse.
Notably, many cases of DCL displayed complex (often
unusual) karyotypes, with aneuploidy in 30%.
Residual effects of cytotoxic chemotherapy
HSCT recipients are at significantly increased risk
of secondary malignancies. One study of 557 BMT
recipients revealed a cancer rate 5.13 times higher
than expected, with actuarial risk 4.2% at 10 years.
Most were epithelial carcinomas of the skin and mouth
(45.7%), but hematologic malignancies accounted for
11.4% [103]. Although multifactorial, the carcino-
genic effects of cytotoxic chemotherapy play a major
role. Therapy-related AML (t-AML) comprises 5%
to 10% of all AML cases, having been appreciated first
in long-term survivors of Hodgkin lymphoma [104].
Two distinct patterns have been described. The
more common occurs 5 to 7 years after exposure to al-
kylating agents, often preceded by an antecedant MDS
phase (typically lasting 6-12months) and characterized
by deletions involving chromosomes 5 or 7, 18, 121,
unbalanced translocations, and complex karyotype.
The other occurs 1 to 5 years after exposure to topoi-
somerase II (TII)-inhibitors. TII inhibition prevents
efficient unwinding of DNA during replication leading
to DNA strand breaks; intranuclear religation can fa-
cilitate illegitimate, nonhomologous recombinations,
forming potentially leukemogenic translocations
commonly involving 11q23 and 21q22 (sites of MLL
and AML1 genes, respectively). Other associations in-
clude deletions of 20q and 12p [105].MLL-rearranged
t-ALL has also been reported [106].
Most HSCT patients have been exposed to these
agents, with 96% having received either an alkylator
or TII-inhibitor with conditioning. Another (#35)
had received busulfan with an earlier CBT [44].
Although timing of HSC infusion is designed to pre-
vent direct exposure to genotoxins, effects might con-
ceivably persist to influence incoming donor HSCs,
either directly or via effects on stromal elements.
Commensurate with this is the frequent observation
of characteristic cytogenetic abnormalities in DCL.
The malignant clone displayed –7 in at least 10 cases,
either alone or with other abnormalities. Two others
displayed deletions/translocations involving chromo-
some 7, whereas MLL or AML1 gene rearrangements
780 Biol Blood Marrow Transplant 17:771-789, 2011D. H. Wisemanoccurred in 5 cases each. In total, cytogenetic abnor-
malities typical of t-AML occurred in at least 47% of
DCL cases. Moreover, in some cases, engrafted donor
HSCs were further exposed to chemotherapy in vivo
within their new host. For example, patient #62 had re-
ceived etoposide and tenoposide for an earlier
recipient-derived ALL recurrence post-HSCT; the
subsequent DCL displayed MLL rearrangement [56].
Stevens described DCL arising in cells from a first do-
nor after successful HSCT from a second (case #61).
Both transplants were conditioned with fludarabine
and cyclophosphamide, exposing the original donor’s
stably engrafted HSCs to potentially genotoxic che-
motherapy; MDS/AML with –7 developed in cells of
first donor origin 10 months later [55].
Bystander radiation damage
Therapeutic irradiation with conditioning has been
linked to DCL leukemogenesis via several mechanisms.
Marmont et al. suggested that oncogenic material, such
as a virusor intact oncogene,might bephysically released
from host leukemic cells by radiation damage and trans-
fect intoDNAof incomingdonorHSCs [13].Havelange
et al. [51] hypothesized that radiation might have an en-
hancing effect on certain oncogenic viruses. Leukemia is
certainly among the most radiogenic of all neoplasms,
with a relatively short latent period from exposure
[107,108]. Studies into the specific leukemogenicity of
therapeutic irradiation have often been confounded
by concomitant cytotoxic chemotherapy; nevertheless,
both pretransplant radiotherapy [109] and TBI condi-
tioning [110] have been identified as independent risk
factors for secondary MDS/AML after autologous
HSCT.
Established dogma in radiation biology attributed
carcinogenicity to direct energy deposition in the nu-
cleus, with DNA ionization converted to potentially
leukemogenic mutations during replication or enzy-
matic DNA repair. Intuitively, the timing of HSC
reinfusion should protect against these direct effects.
However, this paradigm has been challenged by recog-
nition of a radiation-induced bystander effect (RIBE), by
which equivalent biologic effects are observed in non-
irradiated cells, either located nearby or exposed to
medium from other irradiated cells. Studies in the
1950s observed changes in sternal BM of children re-
ceiving splenicir radiation for CML [111], whereas
later findings that plasma from irradiated patients
could induce chromosomal damage in nonirradiated
cells in culture [112] suggested the generation of ‘‘clas-
togenic factors’’: soluble damage signals released into
plasma on exposure to ionizing radiation capable of in-
ducing bystander DNA damage to distant cells in vivo
or nonirradiated cells ex vivo. Clastogenic signals re-
tain functional ability in circulation as demonstrated
by their ability to cross the placenta and induce
chromosomal instability in children whose mothersreceived nonpelvic irradiation during pregnancy
[113]. They also persist in vivo for long periods. Goh
[114] observed increased chromosomal breakages in
leukocytes from normal individuals when cultured
with serum from patients irradiated 10.5 years previ-
ously, whereas transferrable clastogenic activity has
been observed in plasma of atomic bomb survivors
[115] and Chernobyl workers [116] even decades after
exposure. Studies at the cellular level have demon-
strated multiple endpoints of biological damage in by-
stander cells, including micronucleus formation, p53
up-regulation, genomic instability, mutagenesis, and
frank malignant transformation in cell lines [117].
The identity of putative clastogenic factors and
mechanisms by which they are perpetuated remain un-
certain. Some evidence suggests dependence on gap
junction (GJ)-mediated signaling, given that bystander
mutations in cell lines could be inhibited by the GJ in-
hibitors lindane and octanol and in cells lacking GJ
formation [118]. However, evidence from medium
transfer experiments and the observation of distant by-
stander effects confirm that dependence on physical
interaction is not universal. Several candidate soluble
clastogens have been proposed, including aldehydic
breakdown products of lipid peroxidation [119], ino-
sine nucleotides [120], and various cytokines [121].
Oxidative stress and reactive oxygen species (ROS) ap-
pear important because bystander damage is inhibited
by the ROS scavenger superoxide dismutase [122].
ROS can cause various DNA lesions including poten-
tially leukemogenic mutations, and can activate signal-
ing pathways (p53; MAPK) in bystander cells [123].
ROS might also induce a self-perpetuating cycle of
oxidative stress (and persistence of clastogenicity) by
stimulating competent cells to generate further ROS.
From the model of RIBE, it is tempting to specu-
late that TBI might render donated HSCs subject to
similar bystander effects in vivo. Comparisons with
the medium transfer experiments are particularly com-
pelling, given that HSCT represents an analogous
(albeit reversed) context, that is, transfer of cells into
irradiated medium. In some situations, recipient cells
might persist long enough to deliver damage signals
through direct physical contact with incoming donor
HSCs; alternatively, soluble clastogenic factors gener-
ated by irradiated host cells might persist and circulate
to induce genotoxic effects on donor cells, contribut-
ing critical hits toward a leukemic phenotype. Perhaps
the most compelling in vivo evidence derives from ex-
periments in which mice with inherent plasmacyto-
mata were administered melphalan to create a model
of HSCs imbued with preleukemic potential; when
splenocytes were transferred into preirradiated synge-
neic mice, almost all developed acute leukemia of do-
nor origin, implicating a direct leukemogenic effect
of prior irradiation on unstable (but radiation-na€ıve)
donor cells [124]. Although conditioning included
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were exposed to earlier therapeutic (and possibly occu-
pational) irradiation with potential for longstanding
clastogenicity. The ALL patients in cases #10 and #11
had received cranial irradiation pretransplant [19,20],
whereas patients #4, #7, #18, and #28 (3 conditioned
with chemotherapy alone) received radiotherapy
posttransplant for recipient-derived extramedullary
relapses, 15 to 21 months before onset of DCL
[11,15,27,37].
Defective marrow stroma/microenvironment
The BM stroma is a complex microenvironment of
fibroblasts, adipocytes, osteoblasts, macrophages, and
endothelial cells in a supportive matrix of insoluble
proteins, within which crosstalk between stromal com-
ponents and hematopoietic progenitors is mediated by
numerous chemokines/cytokines. Complex interac-
tions are essential for supporting healthy hematopoie-
sis, and perturbation of this equilibrium might play
a role in leukemic transformation in vivo. Most evi-
dence is indirect, but stromal cell layers from patients
withMDS/AML frequently display abnormal cytokine
milieau [125], and leukemia-associated chromosomal
abnormalities have been identified in stromal cells of
MDS and AML patients [126].
The BM stroma plays a key role in facilitating and
supporting hematopoietic reconstitution following
HSCT, as inferred from the observation of augmented
engraftment after cotransplantation of HSCs with ex
vivo–expanded mesenchymal stem cells [127]. Close
physical interaction invariably occurs between donor
HSCs and BM stromal cells, which probably remain
of host origin after HSCT [128]. In the context of
DCL, abnormalities of the recipientmicroenvironment
might be an inherent feature (given its support in devel-
oping 2 distinct malignancies), or could result from
damaging effects of previous treatment.Chemo-/radio-
therapy can inflict considerable damage on BM stromal
elements [129], whereas radiation-induced stromal
damage can aid survival ofHSCs in culture and contrib-
ute toward selection and proliferation of leukemic
clones [130]. Radiation-induced DNA damage induces
a stress response intended to prevent proliferation of
damaged cells resembling an inflammatory-type re-
sponse, including overproduction of ROS [131]. In-
deed, subclinical markers of inflammation remain
significantly elevated (in proportion to radiation dose)
.50 years after exposure [132], and murine evidence
has directly linked induction of inflammation with leu-
kemogenesis after irradiation [133]. Fibroblasts and
macrophages can permanently arrest in an activated
state, continuously generatingROS,probablymediated
by stromal overproduction of transforming growth fac-
tor (TGF)-b [134], which itself promotes survival and
proliferation of AML cells in vitro [135]. Experiments
have shown higher levels of ROS in HSCs coculturedwith irradiated BM stromal cell lines [136], suggesting
that stromal elements rather than irradiated HSCs
might provide the major source of ROS responsible
for RIBE. Inflammatory macrophages are a potent
source of microenvironmental ROS, and although ulti-
mately donor derived following HSCT they are rela-
tively radio-/chemo-resistant and may take months to
be fully replaced by differentiation of donor-derived
monocytes [137]. Their role in carcinogenesis is in-
creasingly recognized [138], and abundant interactions
between host macrophages and donor HSCs likely
occur in the immediate aftermath of HSCT.
The intensive chemical and radiation exposure ex-
perienced by the recipient BM microenvironment
might trigger comparable inflammatory activation
within the stroma, resulting in increased ROS produc-
tion and elevated leukemogenic potential. Other alter-
ations to stromal composition or function might
alternatively contribute to DCL through novel mech-
anisms. In a recent review, Flynn and Kaufman [139]
suggested that DCL leukemogenesis might not be
cell autonomous proposing that dysregulation of the
normal cellular signalling processes play an integral
role. Such an approach represents a hallmark shift
in emphasis away from the stem cell and onto the
microenvironment in understanding the mechanisms
of leukemogenesis.
Impaired immune surveillance
Ordinarily, tumor surveillance prevents autochtho-
nous neoplasia through complex interactions involving
all branches of a competent immune system, to recog-
nize, eliminate, and prevent tolerization to spontane-
ously arising malignant clones. Tumor development
is associated with acquisition of tumor-specific antigens,
providing targets for recognition by host cytotoxic
T-lymphocytes. Progression to clinical malignancy
usually requires induction of anergy to the malignant
clone [140]. Alternatively, themagnitude of an immune
response may be insufficient to quell a rapidly expand-
ing and mutating tumor, because T cells recognizing
any particular antigen are usually present in low num-
bers even in a normal T cell repertoire. T-immunode-
ficiency, an obligate phenomenon following allogeneic
HSCT, predisposes to this outcome.
T cells remain quantitatively and qualitatively sup-
pressed for long periods after HSCT. T-reconstitu-
tion initially involves expansion of a donor-derived
postthymic T cell repertoire transferred with the graft,
primarily memory T cells. These have already under-
gone thymic selection in the donor and so display tol-
erance to donor-derived cells. Exposure to reactivating
viruses, minor HLA antigens, and antigens expressed
by residual leukemia cells result in massive but uneven
T cell expansion, with a skewed repertoire of TCR
affinities [141]. Full immune recovery involves emer-
gence of a new T cell repertoire generated from
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thymic maturation and selection, during which self-
tolerance is achieved. Ideally, this results in a fully
competent mature T cell repertoire, with tolerance
against both recipient cells and donor-derived hemato-
poietic cells. However, T-reconstitution is highly vari-
able and influenced by several factors. The number of
donor T cells present in the graft varies, with signifi-
cantly fewer in BM and CB than PB; furthermore,
T-depletion was deliberately employed in at least 14
DCL cases. Even when T-replete, the early expansion
challenge faced by the graft on exposure to a massive
new antigenic environment could overwhelm the
relatively few competent donor T cells, resulting in
a period of suboptimal surveillance during which re-
sponses to transformed donor HSCs might be im-
paired. Furthermore, the ubiquitous pharmacologic
immunosuppression following HSCT has profound
suppressive effects on T cell function, whereas chronic
GVHD (cGVHD) itself is immunosuppressive and
may predispose to secondary malignancies [142]. De-
tails of posttransplant course were not consistently or
extensively presented in DCL reports, but 23 cases
confirmed that significant cGVHD had occurred.
Regeneration of a mature T cell repertoire also relies
on adequate thymic function in the recipient. This
decreases markedly with age, and studies have shown
distinct age differences in the capacity of the host
thymus to educate donor-derived prethymic precursors
[143]. Thymic function may be additionally damaged
by prior chemo-/radiotherapy. Consequently, abnor-
malities in T cell maturation and function can persist,
perhaps indefinitely, after HSCT [144]. Impaired
function of antigen-presenting cells (APCs) might
also contribute, with dendritic cells known to display
persisting functional abnormalities in the posttrans-
plant period [145].
A pertinent observation is the transient appearance
(and spontaneous disappearance) of potentially preleu-
kemic clones in the early posttransplant period. In
Palka and coworkers’ study of 31 BMT recipients, 1
developed an abnormal clone (45,XX,–16) at 30
months, which later disappeared spontaneously [18].
Sevilla et al. reported a transient donor-derived MDS
(with –7) in a 4-year-old girl after CBT [146]. At 3
months, she displayed frank pancytopenia with mor-
phological features of MDS in BM and –7 in 79%
of nuclei by FISH; however, by 12 months, her blood
count had spontaneously returned to normal, and at 2
years, –7 was present in only 5.5%of cells. The authors
concluded that early clonal instability and impaired
immune surveillance had facilitated engraftment by
a clone bearing –7, but that immune reconstitution en-
abled its gradual eradication and substitution by prog-
eny of normal HSCs responsible for long-term
engraftment [146]. Transient –7 with spontaneous re-
mission has also been described in normal children, inwhom postthymic T cell maturation is an active and
dynamic natural process [147]. T cells present in CB
grafts are na€ıve, because the fetus is exposed to few al-
loantigens in utero; as more CBT are performed, it will
be interesting to observe the prevalence and fate of ab-
normal clones, and whether the paucity of postthymic
passenger T cells translates into increased risk of
malignancy.
Telomere shortening and replicative stress
Telomeres are nonencoding regions of DNA
flanking the ends of chromosomes, comprising a vari-
able number of tandemly repeated TTAGGG motifs
and associated proteins. They play a critical role in
the maintenance of chromosomal integrity. Because
DNA replication by DNA polymerase is a unidirec-
tional process, loss of a small segment from the 50
end of each strand inevitably occurs with each cell
division. This ‘‘end-replication problem’’ results in
progressive telomere shortening (by 50 to 100 bp
per division [148]). In postmitotic cells, critical telo-
mere shortening usually results in senescence, a state of
irreversible cell cycle arrest triggered by recognition
of the unprotected end as a conventional DNA break
capable of inducing p53-mediated DNA repair. Con-
sequently, most somatic cells have a finite lifespan, be-
coming senescent after 40 to 80 population doublings
in vitro [149]. Certain cells, however, maintain telo-
mere length and proliferative capacity through expres-
sion of telomerase, a reverse transcriptase capable of
synthesizing terminal nucleotides. Telomerase expres-
sion is variably high in cells endowed with self-renewal
capacity, including HSCs [150], and correlates
strongly with histologic evidence of malignant cells
in many tissues [151]. Although critical telomere
shortening usually triggers senescence, cells with
dysfunctional p53 or other DNA repair pathways
(and lacking telomerase) continue to proliferate until
entering crisis, a state characterized by extremely short
telomeres, genomic instability, and widespread apo-
ptosis. Unprotected telomere ends of proliferating
cells in crisis are prone to illegitimate fusion and
generation of complex, nonreciprocal, potentially
carcinogenic translocations [151].
Although defective telomere homeostasis is impli-
cated in many tumors, studies in hematologic malig-
nancies are confounded by the variable telomerase
expression of normal HSCs. Nevertheless, progressive
telomere shortening is described in leukemia, and
although this might be a result (rather than cause) of
rapid clonal expansion, critical telomere shortening
and resultant genomic instability might promote
disease evolution. Shorter telomeres and telomerase
up-regulation have been observed in AML blasts at di-
agnosis and relapse (compared with remission samples
[152] and healthy controls [153]). Higher telomerase
levels have also been correlated with presence of
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prognosis [155]. Swiggers et al. showed universally
short telomeres in AML blasts displaying chromo-
somal aberrations that could theoretically result from
telomere dysfunction, suggesting that telomere short-
ening may contribute to chromosomal instability in
AML development [156]. Patients with dyskeratosis
congenita, an inherited BM failure syndrome charac-
terized by defective telomere maintenance, also display
significantly higher rates of MDS/AML [157].
Under normal circumstances, adult HSCs gener-
ate1011 blood cells each day. Thus, even homeostasis
represents a considerable replicative challenge, but
rapid induction of senescence is largely abrogated by
high telomerase expression. Despite containing rela-
tively few HSCs, the donor graft faces a still greater
proliferative demand to rapidly repopulate the recipi-
ent’s entire hematopoietic system. The mitotic rate
required to meet this expansion challenge imposes
considerable replicative stress and corresponding
increase in telomere attrition. Several studies have
documented significant (and accelerated) telomere
shortening following HSCT. Notaro et al. [158] ob-
served consistently shorter telomeres (by 79 to 1,446
bp) in granulocytes of 11 HSCT recipients compared
with respective donors, inversely correlating with nu-
cleated cell dose infused. Wynn et al. [159] detected
shorter telomeres (by mean 400 bp) in leukocytes of
14 HSCT recipients compared with donors, equiva-
lent to an estimated 15 years’ aging; others have esti-
mated telomere attrition equivalent to .50 years’
aging in normal controls [160]. Similar trends were ob-
served after NMA HSCT [161], implicating replica-
tive stress (rather than effects of conditioning) as the
principal mediating factor. Interestingly, this appears
restricted to the first year posttransplant, with only mi-
nor telomere shortening (comparable with normal
levels) thereafter [162]: kinetics that intuitively fit
with a period of early replicative stress followed by
normalization once recipient hematopoiesis is re-
stored. The combination of replicative stress, altered
telomere maintenance, and genomic instability might
predict the early onset of clonal hematopoietic disor-
ders in engrafted donor cells.Figure 3. Kaplan-Meier curve depicting overall survival (OS) in all re-
ported cases of donor cell leukemia (DCL). Overall, at least 34 patients
had died before publication, at a median of 5.5 months after DCL diag-
nosis. At least 24 patients remained alive at publication, at a median of 14
months follow-up. Reinduction chemotherapy with apparently curative
intent had been attempted in at least 47 cases. Detailed outcome data
were available for 41 patients. Median OS for treated patients was
estimated at 32.8 months (95% confidence interval: 22.5-43.1 months).
For the Kaplan-Meier estimate, surviving patients were censored at last
reported follow-up. Insufficient datawere provided for analysis of event-
free survival (EFS) or other detailed outcome parameters.Treatment of DCL
DCL is considered to carry an extremely poorprog-
nosis, consistent with other secondary leukemias.Over-
all, this appears to hold, with at least 34 patients (53%)
having died before publication, at a median 5.5 months
after DCL diagnosis (range: 1 week-64 months). How-
ever, at least 24 of the remaining 30were evidently alive
at publication, after median follow-up of 14 months.
Prognostication is hampered by the small number of re-
ported cases, variable follow-up, and range of treatment
strategies employed.Nevertheless, durable responses tosalvage treatment were clearly achieved. Of the 24 sur-
viving patients, at least 17 (71%) were reportedly in
complete remission (CR) at time of publication, with
4 others on active treatment. Mean overall survival
(OS) for treated patients was 32.8 months (95% confi-
dence interval [CI]: 22.5-43.1) (Figure 3).
Reinduction chemotherapy with curative intent
was attempted in 47 (of 52) DCL patients, employing
a range of standard AML- or ALL-specific regimens
(Table S1). No/minimal response occurred in 16 cases,
and in another, reinduction resulted in aplasia preclud-
ing further treatment (case #43) [6]. Nevertheless, CR
was achieved in at least 27 patients, remaining durable
in 16 of these. CR was achieved in 13 of 17 (76%)
donor-ALL patients, with 7 still in remission at me-
dian 12 months follow-up. At least 16 of 34 (53%)
donor-AML patients entered CR, with another still
on treatment; remissions persisted in at least 10 of
these (33%) at median 17 months follow-up. A second
allogeneic HSCT was performed in 17 patients of
whom at least 7 (41%) remained alive (in CR) at a me-
dian of 29 months from diagnosis of DCL. Three pa-
tients were awaiting second HSCT (in CR) at time of
publication. At least 7 patients subjected to second
HSCT subsequently relapsed and died. One patient
achieved a 44-month remission with reinduction
before relapse of DCL prompted second BMT, but
despite again responding, she relapsed and died 12
months later. Salla-Torra and coworker’s cohort in-
cluded 3 DCL cases whose treatment included second
HSCT, and although patient fate was not clearly
stated, durable responses were probably achieved
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months). Thus, durable remissions can be obtained
with standard reinduction strategies, particularly
when consolidated with second HSCT.
Intuitively, an alternative donor would seem
preferable for second HSCT, given that significant
graft-versus-leukemia (GVL) effect would not be
anticipated in the total absence of HLA disparity
between donorT cells and the leukemic clone. Intrigu-
ingly though, Jacobs et al. (case #62) successfully em-
ployed T-replete BMT from the original donor in
a patient with donor-AML, achieving CR durable at
4 years [56]. Rationale offered for selecting this ‘‘semi-
autologous graft’’ included a low probability of graft
rejection while exploiting the unusual opportunity to
combine advantages of autologous transplantation
(eg, lack ofGVHD)with a graft free of disease contam-
ination. The authors suggested that even in this set-
ting, ‘‘GVL reactions may occur.’’ Although identity
of donors was often not stated, at least 4 other patients
also received a second HSCT from their original do-
nor. Overall, 3 (of the 5) achieved durable responses,
supporting Jacobs and coworkers’ suggestion that
‘‘second transplant from the same donormay be a cura-
tive option for these patients.’’ Equally surprising were
the transient responses to donor lymphocyte infusions
(DLI) from original donors observed in 2 DCM cases
(#27 and #30) [36,39]. In the latter, pancytopenia was
corrected entirely following DLI for a 12-month
period, at which point repeat DLI was unsuccessful.
Komrokji et al. hypothesized that acquisition of
additional antigens by the donor clone might have
made it more recognizable to donor lymphocytes.
However, an allogeneic graft-versus-stroma effect on
the BMmicroenvironment (rather than the cells them-
selves) has been proposed, and could theoretically ex-
plain responses observed to both DLI and second
HSCT from original donors. Future DCLsmight pro-
vide unique models for investigating the contribution
of cell-independent immunomodulatory properties
of allogeneic therapy. For now, however, a second
HSCT from an alternative donor would remain
a more logical consolidation strategy in DCL.Ethical Considerations
DCL raises important questions regarding the re-
sponsibility of physicians and registries toward donors
and their families. Although most sibling donors will
be aware of clinical developments in the recipient,
stable family relationships should not be assumed,
and the situation is clearly different for unrelated do-
nors. Feedback to donor registries of adverse events
in recipients is generally encouraged, but although cer-
tain registries and cord banks do advocate donor noti-
fication in the event of detecting a potentially treatable
abnormality, this is rarely a compulsory requirement,and the lack of centralization and international nature
of many modern donations can make this practically
difficult. Most donor registries have specific policies
for sharing information on the recipient’s progress
with donors, although feedback of adverse outcomes
is generally discouraged to prevent misplaced feelings
of guilt in the donor. Nevertheless, many transplant
centers will agree to provide donors with progress
updates, or even permit limited communication with
the recipient provided both parties have consented.
However, how this applies to DCL is unclear because
abnormalities are usually undetectable in donor sam-
ples pretransplant, and the clinical implications for
the donor remain unclear. Ethically, there is a strong
argument in favor of notifying a donor when their
HSCs become malignant in another host. Donor trac-
ing would additionally yield useful follow-up informa-
tion on the health of the donor and potentially also on
relevant pathology samples to aid further research into
DCL leukemogenesis. Conversely, DCL is clearly
multifactorial, and current evidence suggests that
donors are not destined to develop malignancy them-
selves. The EBMT survey inquired about donor health
and revealed no cases of leukemia in donors from the
14 reported cases, at a median follow-up of 9 years
[6]. BM and/or cytogenetic examination were per-
formed in 4 of the donors, with no abnormalities
detected. This larger cohort similarly yielded no
reports of donors developing leukemia.
Consequently, it is difficult to advocate detailed
notification and assessment of unrelated donors on
the basis of risk, and anything more than a simple
health surveillance interview would be difficult to
justify given the potential negative impacts of such
information on a healthy individual’s mindset, rela-
tionships, insurance status, etc. For now, an ad hoc
discretionary approach seems reasonable, based on
local policy and the known wishes of the donors/
recipients involved. The duties of cord banks toward
donors and their parents are particularly difficult to de-
fine, given the unusually high frequency of preleuke-
mic clones demonstrable in CB samples and the
particular sensitivities involved in diagnosing infants
with a preleukemic ‘‘potential’’ of doubtful signifi-
cance. Given that overall risk of the child developing
leukemia appears low (\1%), informing the parents
would seem unwarranted, although this is clearly
open for debate.CONCLUSION
DCL is an intriguing phenomenon, which was
probably underdiagnosed for many years and could
represent up to 5% of all leukemia relapses post-
HSCT. Etiologic mechanisms remain speculative,
but etiology is almost certainly multifactorial, and
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of heterogeneity between cases. New molecular tech-
niques for chimerism monitoring have elevated the
ease, applicability, and reliability of DCL diagnosis
to unprecedented levels, and it is perhaps not surpris-
ing that examples of DCL in the literature have ex-
ploded in parallel. These modern tools are a far cry
from the original controversial claims of donor origin
made on isolated observations of sex mismatch on
karyotype analysis—some of which may have been
erroneous and could be serving to confound/confuse
analysis of the cohort collated herein. It is clear,
though, that DCL as an entity exists and should be
considered in any cases of acute leukemia developing
in the posttransplant period, particularly if features
differ from those of the original disease.With growing
awareness and increasingly sophisticated diagnostic
tools, it should become feasible to report larger series,
with a view to identifying risk factors and optimal
treatment strategies. A greater understanding of the
biology and impact of DCL will raise other issues re-
garding donor recruitment, selection, and notification,
particularly in the context of increasing age of poten-
tial donors and rising popularity of CBT. Future cases
should also provide valuable human models for inves-
tigating mechanisms of leukemogenesis in vivo.ACKNOWLEDGMENTS
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